ClinicalTrials.gg
CompletedNCT02217943Updated Mar 30, 2025

Prospective Metabolic Surgery in T2DM Chinese Subjects

An interventional study of Roux-en-Y gastric bypass and Sleeve gastrectomy in Diabetes and Obesity, sponsored by Ethicon Endo-Surgery. Completed at 6 sites in China. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Ethicon Endo-Surgery (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Diabetes Mellitus by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Johnson & Johnson.

Enrollment
14th of 24
101 · median 129
Started
2014
with 1 other
No phase
10 of 28
none open now
Registered
17th of 28
by date

Among the 28 studies in Diabetes Mellitus by Johnson & Johnson, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2014, is one of 10 with no phase, and was the 17th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 28 studies in Diabetes Mellitus by Johnson & Johnson is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Diabetes Mellitus by Johnson & Johnson as a file.
02

Study summary

The primary goal of this study is to assess impact of metabolic surgery on glycemic control in diabetic patients.

Read the detailed description

The primary objective of this study is to assess the impact of metabolic surgery (Roux-en-Y gastric bypass [RYGB] or sleeve gastrectomy [SG]) on composite measure of glycemic control at 2 years post surgery in a Type 2 Diabetes Mellitus (T2DM) cohort of subjects.

03

Conditions studied

  • Diabetes
  • Obesity
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 20 to 60 years of age (inclusive) on the date the document (ICD) is signed;
  2. A (BMI) from 28 kg/m2 to 50 kg/m2 ;
  3. Previously diagnosed for at least 6 months with T2DM according to World Health Organization (WHO) criteria;
  4. C-peptide > 1 ng/mL (0.3 nmol/L);
  5. Able and willing to comply with procedures required by the protocol; and
  6. Able to comprehend and sign or, if illiterate, leave their thumb impression on the study ICD.

Exclusion criteria

Exclusion Criteria:

  1. History of T2DM for a duration > 10 years;
  2. History of drug and/or alcohol abuse within 2 years of Screening Visit;
  3. Any previous major GI surgery (e.g., any GI surgery with a resection, etc.). Previous GI surgery allowed include: appendectomy, gall bladder surgery, liver , and endoscopic procedures;
  4. Scheduled concurrent surgical, non-endoscopy, procedure from Visit 1 through the end of Visit 3;
  5. Women of who are pregnant or lactating at the time of screening, at the time of surgery, or planning to become pregnant one year or sooner after the surgery;
  6. Psychiatric disorders that may affect compliance with the clinical study, including dementia, active psychosis, severe depression, or history of suicide attempts;
  7. Any of the following conditions:

    1. Inflammatory diseases of the GI tract, including severe intractable esophagitis, gastric ulceration, duodenal ulceration, or specific inflammation such as Crohn's disease or ulcerative colitis that have been active within the past 10 years;
    2. End stage renal disease;
    3. Abnormal results from glutamic acid decarboxylase autoantibodies (GADA) or protein tyrosine phosphatase-like protein (IA-2A) testing; or
    4. such as that resulting from chronic oral use, cancer chemotherapeutic agents, or immune deficiency disorders;
  8. Participation in any other clinical study (not to include registries or survey-only studies) within 30-days or 5 half-lives of an drug (which ever is longer), of Visit 1 (Screening Visit) and for the duration of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Active comparator
    Roux-en-Y gastric bypass

    Subjects who receive a Roux-en-Y gastric bypass

    Procedure: Roux-en-Y gastric bypass

  • Active comparator
    Sleeve Gastrectomy

    Subjects who receive a sleeve gastrectomy

    Procedure: Sleeve gastrectomy

Interventions

  • ProcedureRoux-en-Y gastric bypass
  • ProcedureSleeve gastrectomy
06

What researchers measure

Primary outcomes

  1. Composite Measure of Glycemic Control - Complete Remission

    Normal measures of glucose metabolism (glycosylated hemoglobin A1c \[HbA1c\] \< 6% \[7.0 mmol/L\] and fasting plasma glucose \[FPG\] \< 100 mg/dL \[5.6 mmol/L\]) for 1 year in the absence of antidiabetic medications;

    Time frame: 2 years

  2. Composite Measure of Glycemic Control - Partial remission

    Hyperglycemia (HbA1c 6% - 6.4% \[7.0 - 7.6 mmol/L\] and FPG 100 - 125 mg/dL \[5.6 mmol/L - 6.9 mmol/L\]) for 1 year in the absence of anti-diabetic medications;

    Time frame: 2 years

  3. Composite Measure of Glycemic Control - Improvement

    Significant reduction in HbA1c (by \> 1%) or FPG (\> 25 mg/dL \[1.4 mmol/L\]) OR reduction in HbA1c and FPG accompanied by a decrease in antidiabetic medication requirement (by discontinuing insulin or 1 oral agent, or ½ reduction in dose) for at least 1-year duration;

    Time frame: 2 years

  4. Composite Measure of Glycemic Control - Unchanged

    The absence of remission or improvement as described earlier;

    Time frame: 2 years

  5. Composite Measure of Glycemic Control - Recurrence

    FPG or HbA1c in the diabetic range (≥ 126 mg/dL \[7.0 mmol/L\] and ≥ 6.5% \[7.8 mmol/L\], respectively) OR need for antidiabetic medication after initial complete or partial remission.

    Time frame: 2 years

Secondary outcomes

  1. Composite Measure of Glycemic Control

    The composite measure of glycemic control will be defined as previously described in the primary outcome measure.

    Time frame: 5 years

  2. Evaluation of diabetic nephropathy

    Evaluate long-term diabetic nephropathy

    Time frame: 5 years

  3. Evaluation of diabetic retinopathy

    Evaluate long-term diabetic retinopathy.

    Time frame: 5 years

  4. Assess changes in HbA1c

    Assess changes in HbA1c after the procedure is performed.

    Time frame: 5 years

  5. Assess changes in Weight (kg)

    Assess changes in weight after the procedure is performed.

    Time frame: 5 years

  6. Assess changes in BMI

    Assess changes in BMI after the procedure is performed.

    Time frame: 5 years

  7. Assess changes in high-density lipoprotein (HDL) (mg/dL and mmol/L)

    Assess changes in high-density lipoprotein (HDL) (mg/dL and mmol/L) after the procedure is performed

    Time frame: 5 years

  8. Assess changes in low-density lipoprotein (LDL) (mg/dL and mmol/L

    Assess changes in low-density lipoprotein (LDL) (mg/dL and mmol/L) after the procedure is performed.

    Time frame: 5 years

  9. Assess changes in triglycerides (TG) (mg/dL and mmol/L)

    Assess changes in triglycerides (TG) (mg/dL and mmol/L) after the procedure is performed.

    Time frame: 5 years

  10. Assess changes in cholesterol (mg/dL and mmol/L)

    Assess changes in cholesterol (mg/dL and mmol/L) after the procedure is performed.

    Time frame: 5 years

  11. Assess changes in FPG (mg/dL and mmol/L)

    Assess changes in FPG (mg/dL and mmol/L) after the procedure is performed

    Time frame: 5 years

  12. Assess changes in insulin (µU/mL and pmol/L)

    Assess changes in insulin (µU/mL and pmol/L) after the procedure is performed

    Time frame: 5 years

  13. Assess changes in serum albumin level (g/L)

    Assess changes in serum albumin level (g/L) after the procedure is performed

    Time frame: 5 years

  14. Assess changes in alanine aminotransferase (ALT) level (Unit [U]/L)

    Assess changes in alanine aminotransferase (ALT) level (Unit \[U\]/L) after the procedure is performed

    Time frame: 5 years

  15. Assess changes in aspartate aminotransferase (AST) level (U/L)

    Assess changes in aspartate aminotransferase (AST) level (U/L) after the procedure is performed

    Time frame: 5 years

  16. Assess changes in gamma-glutamyl transferase (GGT) level (U/L)

    Assess changes in gamma-glutamyl transferase (GGT) level (U/L) after the procedure is performed

    Time frame: 5 years

  17. Assess changes in creatinine levels (mg/dL and mmol/L)

    Assess changes in creatinine levels (mg/dL and mmol/L) after the procedure is performed

    Time frame: 5 years

  18. Assess changes in blood urea nitrogen (BUN) levels (mg/dL and mmol/L)

    Assess changes in blood urea nitrogen (BUN) levels (mg/dL and mmol/L) after the procedure is performed

    Time frame: 5 years

  19. Assess changes in anti-hypertensive medication

    Assess changes in anti-hypertensive medication after the procedure is performed

    Time frame: 5 years

  20. Asses the changes in lipid lowering medication

    Asses the changes in lipid lowering medication after the procedure is performed

    Time frame: 5 years

  21. Assess the changes in hyperglycemia medication

    Assess the changes in hyperglycemia medication after the procedure is performed

    Time frame: 5 years

  22. Assess the changes in SF-36 Health Survey

    Assess the changes in SF-36 Health Survey after the procedure is performed

    Time frame: 5 years

07

Study locations

6 sites
  • Beijing Shijitan Hospital
    Beijing, China
  • China-Japan Union Hospital of Jilin University
    Changchun, China
  • Guangzhou Overseas Chinese Hospital
    Guangzhou, China
  • Jiangsu Province Hospital
    Jiangsu, China
  • Shanghai East Hospital
    Shanghai, China
  • Shanghai No. 6 People's Hospital
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Jun 2018, 46 months.

Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 46 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Aug 15, 2014
StartActual
Jul 31, 2014
Primary completionActual
Jun 5, 2018
CompletionActual
Apr 11, 2021
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02217943
Responsible party
Sponsor
First posted
Aug 15, 2014
Start date
Jul 31, 2014
Primary completion
Jun 5, 2018
Completion
Apr 11, 2021
Last update
Mar 30, 2025

Study contacts

Robin Scamuffa
study director · Ethicon, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion